CA2350635A1 - Therapeutic product and its use - Google Patents
Therapeutic product and its use Download PDFInfo
- Publication number
- CA2350635A1 CA2350635A1 CA002350635A CA2350635A CA2350635A1 CA 2350635 A1 CA2350635 A1 CA 2350635A1 CA 002350635 A CA002350635 A CA 002350635A CA 2350635 A CA2350635 A CA 2350635A CA 2350635 A1 CA2350635 A1 CA 2350635A1
- Authority
- CA
- Canada
- Prior art keywords
- tramadol
- enantiomer
- product according
- racemic
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The present invention is based on the discovery that, by employing certain, non-racemic, proportions of the respective enantiomers of tramadol, the most beneficial therapeutic index, in terms of analgesic efficacy and reduction o f side effects (e.g. nausea, vomiting, dizziness, constipation, sedation and others) associated with administration of the racemate, may be achieved.</SD OAB>
Description
THERAPEUTIC PRODUCT A~3D ITS USE
Field of the Invention The present invention relates to a novel, non-racemic, form of tramadol, and its use in analgesia.
background of the Invention Tramadol (cis-2-dimethylaminomethyl-1-(3-methoxy-phenyl) -1-cyclohexanol) is a chiral drug substance which is used as a high-potency analgesic agent. Although tramadol is currently marketed as the racemate only, there has been considerable interest in the physiological properties associated with its individual enantiomers, namely 1S,2S-(-)-tramadol and iR,2R-(+)-tramadol, the latter being shown below (1).
(1) In particular, the analgesic efficacy and safety of the racemate and the individual enantiomers have been investigated in a randomised, double-blind study with gynaecological patients using intravenous patient-controlled analgesia; see S. Grond et a1, Pain (1995) 62 :313-320. Although (+)-tramadol appeared to be more potent in producing analgesia, it also produced more nausea and vomiting. Since the racemate has more efficacy than (-)-tramadol and no more side effects than (+)-tramadol, the authors concluded that the racemate had more clinical utility.
In another study it was shown that there is complementary and synergistic antinociceptive interaction between the individual enantiomers of tramadol; see R.B.
Raffa et a1, J Pharmacol. Exp. Ther. (1993) 67 : 331-340. The enantiomers have different potencies at opioid receptors, and in inhibiting serotonin re-uptake and noradrenaline re-uptake. It therefore appears that both enantiomers of tramadol contribute to the analgesic effect.
Summary of the Invention The present invention is based on the discovery that, by employing certain, non-racemic, proportions of the respective enantiomers of tramadol, the most beneficial therapeutic index, in terms of analgesic efficacy and reduction of side effects (e. g. nausea, vomiting, dizziness, constipation, sedation and others) associated with administration of the racemate, may be achieved.
According to a first aspect of the present invention a product comprises a non-racemic mixture of the single enantiomers of tramadol as a combined preparation (kit) for simultaneous, separate or sequential use in the treatment or prevention of pain.
According to a second aspect of the present invention, a non-racemic mixture of the single enantiomers of tramadol is used in the manufacture of a medicament for the treatment or prevention of pain, and is particularly useful for the treatment of patients disposed to side effects typically associated with the administration of racemic tramadol. The medicament is, however, useful in treating other patient types, as discussed below.
According to a third aspect of the claimed invention, a product comprises a non-racemic mixture of the single enantiomers of tramadol and a pharmaceutically-acceptable carrier.
Detailed Description of the Invention In the context of the present Application, when reference is made to a non-racemic mixture of tramadol this is intended to include enantiomerically-pure (-)-tramadol, or enantiomeric excesses in respect of (-)-tramadol approaching enantiomeric purity.
Typically, the non-racemic mixture for use in the present invention comprises at least 60 wt.% (-)-tramadol.
While enantiomerically-pure (-)-tramadol may be useful in achieving analgesia, it is preferred that (-)-tramadol be formulated with at least some (+)-tramadol, as with both enantiomers present the optimal balance between analgesic efficacy and safety is achieved. Particularly preferred weight ratios of the two enantiomers lie in the range 10-40:90-60 (+)-tramadol:(-)-tramadol (+:-), more preferred ratios lie in the range 20-40:80-60 (+:-), and the most preferred ratios lie in the range 30-40:70-60 (+:-).
These preferred non-racemic mixtures are particularly useful in the treatment of patients who are disposed to side effects typically associated with the administration of racemic tramadol. A couple of examples of such side effects are given above. Other side effects typically observed in the administration of racemic tramadol include blurred vision, drowsiness, somnolence, hallucinations, respiratory depression, and euphoria. The present invention, however, is particularly useful in treating those patients prone to nausea and vomiting. This is because, as is explained in the Example below, (-) -tramadol is believed to modulate the emetic properties of (+)-tramadol, thereby reducing the overall emetic capability of racemic tramadol. This effect can be exploited for maximum benefit using different release profiles for the different enantiomers, as is discussed below.
The present invention is also believed to be particularly suited to the treatment of patients exhibiting abnormal CYP2D6 liver enzyme activity. The CYP2D6 gene encoding sparteine oxygenase is highly polymorphic, and an ever-increasing number of mutations are being identified.
The wild-type gene is CYP2D6*lA. Any person not having the wild-type gene can be categorised as exhibiting abnormal enzyme activity. The precise nature of any particular mutation determines the degree to which a patient exhibits abnormal enzyme activity. Thus, by applying simple laboratory genetic analysis techniques it is possible to ascertain the approximate rate at which (+)-tramadol will be metabolised by a particular patient, and therefore how rapid and effective analgesia will be.
Field of the Invention The present invention relates to a novel, non-racemic, form of tramadol, and its use in analgesia.
background of the Invention Tramadol (cis-2-dimethylaminomethyl-1-(3-methoxy-phenyl) -1-cyclohexanol) is a chiral drug substance which is used as a high-potency analgesic agent. Although tramadol is currently marketed as the racemate only, there has been considerable interest in the physiological properties associated with its individual enantiomers, namely 1S,2S-(-)-tramadol and iR,2R-(+)-tramadol, the latter being shown below (1).
(1) In particular, the analgesic efficacy and safety of the racemate and the individual enantiomers have been investigated in a randomised, double-blind study with gynaecological patients using intravenous patient-controlled analgesia; see S. Grond et a1, Pain (1995) 62 :313-320. Although (+)-tramadol appeared to be more potent in producing analgesia, it also produced more nausea and vomiting. Since the racemate has more efficacy than (-)-tramadol and no more side effects than (+)-tramadol, the authors concluded that the racemate had more clinical utility.
In another study it was shown that there is complementary and synergistic antinociceptive interaction between the individual enantiomers of tramadol; see R.B.
Raffa et a1, J Pharmacol. Exp. Ther. (1993) 67 : 331-340. The enantiomers have different potencies at opioid receptors, and in inhibiting serotonin re-uptake and noradrenaline re-uptake. It therefore appears that both enantiomers of tramadol contribute to the analgesic effect.
Summary of the Invention The present invention is based on the discovery that, by employing certain, non-racemic, proportions of the respective enantiomers of tramadol, the most beneficial therapeutic index, in terms of analgesic efficacy and reduction of side effects (e. g. nausea, vomiting, dizziness, constipation, sedation and others) associated with administration of the racemate, may be achieved.
According to a first aspect of the present invention a product comprises a non-racemic mixture of the single enantiomers of tramadol as a combined preparation (kit) for simultaneous, separate or sequential use in the treatment or prevention of pain.
According to a second aspect of the present invention, a non-racemic mixture of the single enantiomers of tramadol is used in the manufacture of a medicament for the treatment or prevention of pain, and is particularly useful for the treatment of patients disposed to side effects typically associated with the administration of racemic tramadol. The medicament is, however, useful in treating other patient types, as discussed below.
According to a third aspect of the claimed invention, a product comprises a non-racemic mixture of the single enantiomers of tramadol and a pharmaceutically-acceptable carrier.
Detailed Description of the Invention In the context of the present Application, when reference is made to a non-racemic mixture of tramadol this is intended to include enantiomerically-pure (-)-tramadol, or enantiomeric excesses in respect of (-)-tramadol approaching enantiomeric purity.
Typically, the non-racemic mixture for use in the present invention comprises at least 60 wt.% (-)-tramadol.
While enantiomerically-pure (-)-tramadol may be useful in achieving analgesia, it is preferred that (-)-tramadol be formulated with at least some (+)-tramadol, as with both enantiomers present the optimal balance between analgesic efficacy and safety is achieved. Particularly preferred weight ratios of the two enantiomers lie in the range 10-40:90-60 (+)-tramadol:(-)-tramadol (+:-), more preferred ratios lie in the range 20-40:80-60 (+:-), and the most preferred ratios lie in the range 30-40:70-60 (+:-).
These preferred non-racemic mixtures are particularly useful in the treatment of patients who are disposed to side effects typically associated with the administration of racemic tramadol. A couple of examples of such side effects are given above. Other side effects typically observed in the administration of racemic tramadol include blurred vision, drowsiness, somnolence, hallucinations, respiratory depression, and euphoria. The present invention, however, is particularly useful in treating those patients prone to nausea and vomiting. This is because, as is explained in the Example below, (-) -tramadol is believed to modulate the emetic properties of (+)-tramadol, thereby reducing the overall emetic capability of racemic tramadol. This effect can be exploited for maximum benefit using different release profiles for the different enantiomers, as is discussed below.
The present invention is also believed to be particularly suited to the treatment of patients exhibiting abnormal CYP2D6 liver enzyme activity. The CYP2D6 gene encoding sparteine oxygenase is highly polymorphic, and an ever-increasing number of mutations are being identified.
The wild-type gene is CYP2D6*lA. Any person not having the wild-type gene can be categorised as exhibiting abnormal enzyme activity. The precise nature of any particular mutation determines the degree to which a patient exhibits abnormal enzyme activity. Thus, by applying simple laboratory genetic analysis techniques it is possible to ascertain the approximate rate at which (+)-tramadol will be metabolised by a particular patient, and therefore how rapid and effective analgesia will be.
In accordance with the present invention it is envisaged that patients phenotypically or genotypically diagnosed as extensive metabolizers of racemic tramadol will particularly benefit from administration of non-racemic tramadol, since they are especially prone to side-effects such as nausea and vomiting. Furthermore, the administration regime may be tailored to suit any individual patient once his or her CYP2D6 genotype is known.
Other non-racemic ratios of the two tramadol enantiomers are also useful in the treatment or prevention of pain, depending upon the cause of the pain and/or the patient to be treated. For instance, mixtures comprising a very high proportion of (-)-tramadol may be used, for example weight ratios in the range 0-10:100-90 (+:-), with patients particularly disposed to side effects associated with racemic tramadol. Another option is to employ a more even balance of the two enantiomers, with the more efficacious (+)-enantiomer in excess, for instance weight ratios in the range 60-80:40-20 (+:-), typically 60-70:40-(+:-). Such ratios may be useful in treating patients not particularly disposed to side effects associated with racemic tramadol, or where analgesic efficacy is of primary importance. Administration of (-)-tramadol before or at a 25 faster rate than (+)-tramadol would, however, still be beneficial in reducing side effects.
In the context of the present Application, all quoted weight ratios should be interpreted as including a tolerance of, say, i 5 wt.%.
30 The present invention is also believed to be particularly useful in the treatment of the pain and/or other effects associated with migraine. To this end, a further aspect of the present invention is the use of a non-racemic mixture of the single enantiomers of tramadol in the manufacture of a medicament for the prevention or treatment of migraine.
The amount of non-racemic tramadol administered to any particular patient will depend upon the patient and the conditions for which the non-racemic tramadol is administered, and on whether non-racemic tramadol is to be 5 used in prophylaxis or in therapy. Suitable amounts for administration are readily derivable by the skilled person.
The different enantiomers of tramadol may be administered simultaneously, separately or sequentially.
They may be formulated for either immediate or controlled release, or a combination of the two, or for release at different rates, or at different times. Preferred modes of administration release (-)-tramadol before or at a faster rate than (+)-tramadol, so as to optimise the effect of (-)-tramadol on the emetic properties of (+)-tramadol.
Although, situations may be envisaged, where the reverse may be required, and it is desired to administer (+)-tramadol before or at a faster rate than (-)-tramadol.
A particularly preferred mode of administration is with (-)-tramadol in immediate release form and (+) tramadol in controlled release form, by employing a combination of immediate and controlled release technologies, as described in Wo-A-9840053, the contents of which are incorporated herein by way of reference. It is envisaged that a dosage form of this type may be particularly beneficial in achieving rapid analgesia without the concomitant side effects associated with administration of racemic tramadol.
A number of different types of dosage form can be envisaged for the non-racemic mixtures of the present invention, for administration by a variety of routes, e.g.
oral, rectal, transdermal, nasal, ophthalmic, pormonary and injectable (subcutaneous or intravenous). Suitable dosage forms include, fox example, tablets, suppositories, capsules, e.g. containing multiparticulates, patches, polymer implants, aerosols, liposomes or microparticulates for injection, and any other conventional dosage form.
Other non-racemic ratios of the two tramadol enantiomers are also useful in the treatment or prevention of pain, depending upon the cause of the pain and/or the patient to be treated. For instance, mixtures comprising a very high proportion of (-)-tramadol may be used, for example weight ratios in the range 0-10:100-90 (+:-), with patients particularly disposed to side effects associated with racemic tramadol. Another option is to employ a more even balance of the two enantiomers, with the more efficacious (+)-enantiomer in excess, for instance weight ratios in the range 60-80:40-20 (+:-), typically 60-70:40-(+:-). Such ratios may be useful in treating patients not particularly disposed to side effects associated with racemic tramadol, or where analgesic efficacy is of primary importance. Administration of (-)-tramadol before or at a 25 faster rate than (+)-tramadol would, however, still be beneficial in reducing side effects.
In the context of the present Application, all quoted weight ratios should be interpreted as including a tolerance of, say, i 5 wt.%.
30 The present invention is also believed to be particularly useful in the treatment of the pain and/or other effects associated with migraine. To this end, a further aspect of the present invention is the use of a non-racemic mixture of the single enantiomers of tramadol in the manufacture of a medicament for the prevention or treatment of migraine.
The amount of non-racemic tramadol administered to any particular patient will depend upon the patient and the conditions for which the non-racemic tramadol is administered, and on whether non-racemic tramadol is to be 5 used in prophylaxis or in therapy. Suitable amounts for administration are readily derivable by the skilled person.
The different enantiomers of tramadol may be administered simultaneously, separately or sequentially.
They may be formulated for either immediate or controlled release, or a combination of the two, or for release at different rates, or at different times. Preferred modes of administration release (-)-tramadol before or at a faster rate than (+)-tramadol, so as to optimise the effect of (-)-tramadol on the emetic properties of (+)-tramadol.
Although, situations may be envisaged, where the reverse may be required, and it is desired to administer (+)-tramadol before or at a faster rate than (-)-tramadol.
A particularly preferred mode of administration is with (-)-tramadol in immediate release form and (+) tramadol in controlled release form, by employing a combination of immediate and controlled release technologies, as described in Wo-A-9840053, the contents of which are incorporated herein by way of reference. It is envisaged that a dosage form of this type may be particularly beneficial in achieving rapid analgesia without the concomitant side effects associated with administration of racemic tramadol.
A number of different types of dosage form can be envisaged for the non-racemic mixtures of the present invention, for administration by a variety of routes, e.g.
oral, rectal, transdermal, nasal, ophthalmic, pormonary and injectable (subcutaneous or intravenous). Suitable dosage forms include, fox example, tablets, suppositories, capsules, e.g. containing multiparticulates, patches, polymer implants, aerosols, liposomes or microparticulates for injection, and any other conventional dosage form.
Particularly preferred dosage forms are described in WO-A-9840053. Of the dosage forms described in that document, a bilayered tablet is particularly preferred, including (-)-tramadol for immediate release in one layer and (+)-tramadol for controlled release in another layer.
The results upon which the present invention are based are reported in the following Example.
E a a .
The objective was to identify the optimal range of enantiomeric ratios capable of providing the most beneficial therapeutic index, in terms of both analgesic efficacy and reduction of the nausea and vomiting associated with racemic tramadol.
Two studies were carried out to determine analgesic efficacy and emesis of tramadol and its enantiomers in the rat and the ferret, respectively. Comparison of the data obtained in these studies enabled determination of a range of optimal enantiomeric ratios for these species.
Pharnaacokinetic/ pharmacodynamic modelling allowed this data to be extrapolated to humans.
Assessment of Analaesic Efficacv Tramadol and its pure enantiomers were examined for their analgesic efficacy in the rat using the Randall-Selitto test (Arch. Int. Pharmacodyn. (1957) 11 :409-419) in the rat. This test was designed to measure the effect of tramadol and its enantiomers on yeast-induced analgesia, with pain perception being assessed by an increased by increase in pressure to the paw using an analgesy meter.
For comparative purposes the effects of the active metabolites of the tramadol enantiomers, 0-desmethyltramadol, were also tested.
Different amounts of each of the test substances were orally administered to rats, using a constant dose volume of 10 ml/kg. Immediately following administration, 0.1 ml of a 20% w/v suspension of Brewer's yeast in saline was injected subcutaneously into the plantar surface of the right hand paw of each rat to induce hyper-algesia. The left hind paw was similarly injected with 0.1 ml saline, as a control.
Measurements of pressure tolerated were taken from the left (non-inflamed) and right (inflamed) paws 30 minutes after administration of the test substance.
The results observed are illustrated in Figure 1, for the inflamed paw, and Figure 2, for the non-inflamed paw, as a percentage increase in pain tolerance with varying doses of test substance. In both Figures, T = tramadol and M1 = O-desmethyltramadol.
~,ssessment of Nausea Tramadol and its pure enantiomers were examined for their nauseous effects in the ferret. For comparative purposes the effects of the active metabolite of (+)-tramadol, (+)-O-desmethyltramadol ((+)-M1), were also tested. Orally-dosed ferrets were observed over a period of 4 hours for signs of retching and vomiting. Any ferret that retched or vomited over the 4-hour period was regarded as a responder, i.e. as exhibiting nausea.
The results are illustrated in Figure 3; T and M1 represent tramadol and O-desmethyltramadol, as in Figures 1 and 2 . As expected, (+) -M1 is highly emetic . (-) -tramadol is seen to be non-emetic at doses of up to 200 mg/kg. In comparison, (+)-tramadol induces nausea in 75% of ferrets at 50 mg/kg, while the racemate causes nausea in 25% of animals at 100 mg/kg. Although the racemate is a 50:50 mixture of the two enantiomers it is seen to induce less nausea than would be expected based on its content of (+)-enantiomer. This disparity can be explained by the ability of the (-)-enantiomer to modulate emesis associated with the (+)-enantiomer.
Bioanalysis of plasma samples and liver microsome analysis have shown that tramadol is metabolised similarly in the rat, the ferret and the human. It is therefore possible to compare the data obtained in each of these studies, to arrive at the optimal range of enantiomeric ratios for these species. Furthermore, by pharmacokinetic/
The results upon which the present invention are based are reported in the following Example.
E a a .
The objective was to identify the optimal range of enantiomeric ratios capable of providing the most beneficial therapeutic index, in terms of both analgesic efficacy and reduction of the nausea and vomiting associated with racemic tramadol.
Two studies were carried out to determine analgesic efficacy and emesis of tramadol and its enantiomers in the rat and the ferret, respectively. Comparison of the data obtained in these studies enabled determination of a range of optimal enantiomeric ratios for these species.
Pharnaacokinetic/ pharmacodynamic modelling allowed this data to be extrapolated to humans.
Assessment of Analaesic Efficacv Tramadol and its pure enantiomers were examined for their analgesic efficacy in the rat using the Randall-Selitto test (Arch. Int. Pharmacodyn. (1957) 11 :409-419) in the rat. This test was designed to measure the effect of tramadol and its enantiomers on yeast-induced analgesia, with pain perception being assessed by an increased by increase in pressure to the paw using an analgesy meter.
For comparative purposes the effects of the active metabolites of the tramadol enantiomers, 0-desmethyltramadol, were also tested.
Different amounts of each of the test substances were orally administered to rats, using a constant dose volume of 10 ml/kg. Immediately following administration, 0.1 ml of a 20% w/v suspension of Brewer's yeast in saline was injected subcutaneously into the plantar surface of the right hand paw of each rat to induce hyper-algesia. The left hind paw was similarly injected with 0.1 ml saline, as a control.
Measurements of pressure tolerated were taken from the left (non-inflamed) and right (inflamed) paws 30 minutes after administration of the test substance.
The results observed are illustrated in Figure 1, for the inflamed paw, and Figure 2, for the non-inflamed paw, as a percentage increase in pain tolerance with varying doses of test substance. In both Figures, T = tramadol and M1 = O-desmethyltramadol.
~,ssessment of Nausea Tramadol and its pure enantiomers were examined for their nauseous effects in the ferret. For comparative purposes the effects of the active metabolite of (+)-tramadol, (+)-O-desmethyltramadol ((+)-M1), were also tested. Orally-dosed ferrets were observed over a period of 4 hours for signs of retching and vomiting. Any ferret that retched or vomited over the 4-hour period was regarded as a responder, i.e. as exhibiting nausea.
The results are illustrated in Figure 3; T and M1 represent tramadol and O-desmethyltramadol, as in Figures 1 and 2 . As expected, (+) -M1 is highly emetic . (-) -tramadol is seen to be non-emetic at doses of up to 200 mg/kg. In comparison, (+)-tramadol induces nausea in 75% of ferrets at 50 mg/kg, while the racemate causes nausea in 25% of animals at 100 mg/kg. Although the racemate is a 50:50 mixture of the two enantiomers it is seen to induce less nausea than would be expected based on its content of (+)-enantiomer. This disparity can be explained by the ability of the (-)-enantiomer to modulate emesis associated with the (+)-enantiomer.
Bioanalysis of plasma samples and liver microsome analysis have shown that tramadol is metabolised similarly in the rat, the ferret and the human. It is therefore possible to compare the data obtained in each of these studies, to arrive at the optimal range of enantiomeric ratios for these species. Furthermore, by pharmacokinetic/
pharmacodynamic modelling techniques, it is possible to extrapolate the data obtained to humans, to arrive at the optimal range of enantiomeric ratios for use in the present invention.
Claims (20)
1. A product comprising the single enantiomers of tramadol in a non-racemic ratio as a combined preparation (kit) for simultaneous, separate or sequential use in the treatment or prevention of pain.
2. A product according to claim 1, which comprises at least 60% by weight (-)-tramadol.
3. A product according to claim 2 in which the single enantiomers are in a weight ratio of 10-40:90-60 (+:-).
4. A product according to claim 2 in which the single enantiomers are in a weight ratio of 20-40:80-60 (+:-).
5. A product according to claim 2 in which the single enantiomers are in a weight ratio of 0-20:100-80 (+:-).
6. A product according to any preceding claim, which releases the (-)-enantiomer before the (+)-enantiomer.
7. A product according to any of claims 1 to 5, which releases the (-)-enantiomer faster than the (+) -enantiomer.
8. A product according to any of claims 1 to 5, wherein the (-)-enantiomer is in immediate release form and the (+)-enantiomer is in controlled release form.
9. Use of a non-racemic mixture as defined in any of claims 1 to 5 in the manufacture of a medicament for the treatment or prevention of pain.
10. Use according to claim 9, wherein the pain is pain associated with migraine.
11. Use according to claim 9, which is for the treatment of a patient disposed to side effects associated with administration of racemic tramadol.
12. Use according to claim 11, wherein the side effects are selected from nausea, vomiting, dizziness, constipation, sedation, blurred vision, drowsiness, somnolence, hallucinations, respiratory depression, and euphoria, especially nausea and vomiting.
13. Use according to claim 9, which is for the treatment of a patient exhibiting abnormal CYP2D6 liver enzyme activity.
14. Use of a non-racemic mixture as defined in any of claims 1 to 5 in the manufacture of a medicament for the for the treatment or prevention of migraine.
15. A product comprising the single enantiomers of tramadol in a non-racemic ratio, said ratio being defined in any of claims 2 to 5, and a pharmaceutically-acceptable carrier.
16. A product according to claim 15, which releases the (-)-enantiomer before the (+)-enantiomer.
17. A product according to claim 15, which releases the (-)-enantiomer faster than the (+)-enantiomer.
18. A product according to claim 15, wherein the (-)-enantiomer is in immediate release form and the (+)-enantiomer is in controlled release form.
19. A product according to any of claims 15 to 18, which comprises the two enantiomers in separate portions thereof.
20. A product according to claim 19, which is a bilayered tablet comprising (-)-tramadol in one portion thereof, and (+)-tramadol in another, separate, portion thereof.
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9826535.8 | 1998-12-02 | ||
| GB9826537.4 | 1998-12-02 | ||
| GB9826536.6 | 1998-12-02 | ||
| GBGB9826537.4A GB9826537D0 (en) | 1998-12-02 | 1998-12-02 | Therapeutic product and its use |
| GBGB9826536.6A GB9826536D0 (en) | 1998-12-02 | 1998-12-02 | Therapeutic product and its use |
| GBGB9826535.8A GB9826535D0 (en) | 1998-12-02 | 1998-12-02 | Therapeutic product and its use |
| PCT/GB1999/004021 WO2000032558A1 (en) | 1998-12-02 | 1999-12-02 | Therapeutic product and its use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2350635A1 true CA2350635A1 (en) | 2000-06-08 |
Family
ID=27269570
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002350635A Abandoned CA2350635A1 (en) | 1998-12-02 | 1999-12-02 | Therapeutic product and its use |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP1135361A1 (en) |
| JP (1) | JP2002531431A (en) |
| KR (1) | KR20010080364A (en) |
| CN (1) | CN1329590A (en) |
| AU (1) | AU1400100A (en) |
| BR (1) | BR9915873A (en) |
| CA (1) | CA2350635A1 (en) |
| HU (1) | HUP0104420A2 (en) |
| IL (1) | IL142778A0 (en) |
| NO (1) | NO20012738L (en) |
| PL (1) | PL347542A1 (en) |
| WO (1) | WO2000032558A1 (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1164601A (en) | 1999-11-09 | 2001-06-06 | Darwin Discovery Limited | Therapeutic use and formulation |
| BR0114395A (en) * | 2000-10-03 | 2005-08-16 | Penwest Pharmaceuticals Compan | Pharmaceutical composition for oral supply administration |
| DE10108122A1 (en) | 2001-02-21 | 2002-10-02 | Gruenenthal Gmbh | Medicines based on tramadol |
| WO2003048113A1 (en) | 2001-11-30 | 2003-06-12 | Sepracor Inc. | Tramadol analogs and uses thereof |
| RU2008113439A (en) | 2005-09-09 | 2009-10-20 | Лабофарм Инк. (CA) | COMPOSITIONS WITH SLOW DELIVERY OF A MEDICINAL PRODUCT |
| NZ579170A (en) | 2007-02-12 | 2012-05-25 | Dmi Biosciences Inc | Reducing side effects of tramadol |
| BRPI0811639A2 (en) * | 2007-05-31 | 2014-09-30 | Sepracor Inc | FENY CYCLOAKILAMINES REPLACED AS MONOAMINE RECAPTATION INHIBITORS |
| JOP20190251A1 (en) * | 2017-05-31 | 2019-10-21 | Metys Pharmaceuticals AG | Synergistic compositions comprising (r)-dimiracetam (1) and (s)-dimiracetam (2) in a non-racemic ratio |
| WO2019113079A1 (en) | 2017-12-05 | 2019-06-13 | Sunovion Pharmaceuticals Inc. | Nonracemic mixtures and uses thereof |
| WO2019113084A1 (en) | 2017-12-05 | 2019-06-13 | Sunovion Pharmaceuticals Inc. | Crystal forms and production methods thereof |
| BR112021024380A2 (en) | 2019-06-04 | 2022-04-19 | Sunovion Pharmaceuticals Inc | Modified release formulations and uses thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5204116A (en) * | 1991-05-01 | 1993-04-20 | Alza Corporation | Dosage form providing immediate therapy followed by prolonged therapy |
| BR9808325A (en) * | 1997-03-11 | 2000-05-16 | Darwin Discovery Ltd | Dosage forms comprising separate portions of r- and senanciÈmeros |
| DE19807535A1 (en) * | 1998-02-21 | 1999-08-26 | Asta Medica Ag | Drug combination for treating migraine, migraine-type headaches or pain accompanied by nausea, vomiting or delayed gastric emptying |
-
1999
- 1999-12-02 IL IL14277899A patent/IL142778A0/en unknown
- 1999-12-02 JP JP2000585200A patent/JP2002531431A/en active Pending
- 1999-12-02 HU HU0104420A patent/HUP0104420A2/en unknown
- 1999-12-02 CA CA002350635A patent/CA2350635A1/en not_active Abandoned
- 1999-12-02 BR BR9915873-6A patent/BR9915873A/en not_active IP Right Cessation
- 1999-12-02 AU AU14001/00A patent/AU1400100A/en not_active Abandoned
- 1999-12-02 CN CN99813934A patent/CN1329590A/en active Pending
- 1999-12-02 EP EP99973016A patent/EP1135361A1/en not_active Withdrawn
- 1999-12-02 WO PCT/GB1999/004021 patent/WO2000032558A1/en not_active Application Discontinuation
- 1999-12-02 PL PL99347542A patent/PL347542A1/en not_active Application Discontinuation
- 1999-12-02 KR KR1020017005443A patent/KR20010080364A/en not_active Application Discontinuation
-
2001
- 2001-06-01 NO NO20012738A patent/NO20012738L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NO20012738D0 (en) | 2001-06-01 |
| WO2000032558A1 (en) | 2000-06-08 |
| AU1400100A (en) | 2000-06-19 |
| EP1135361A1 (en) | 2001-09-26 |
| JP2002531431A (en) | 2002-09-24 |
| CN1329590A (en) | 2002-01-02 |
| KR20010080364A (en) | 2001-08-22 |
| NO20012738L (en) | 2001-06-01 |
| PL347542A1 (en) | 2002-04-08 |
| BR9915873A (en) | 2001-08-21 |
| HUP0104420A2 (en) | 2002-08-28 |
| IL142778A0 (en) | 2002-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Teoh et al. | Oral manifestations of illicit drug use | |
| Grond et al. | Clinical pharmacology of tramadol | |
| EP1089733B1 (en) | Use of optically pure (+)-norcisapride for treating irritable bowel syndrome | |
| KR19990028983A (en) | Composition consisting of di-threo-methylphenidate and other agents | |
| CA2318921A1 (en) | Pharmacological uses of optically pure (+)-bupropion | |
| NO302736B1 (en) | Pharmaceutical preparation comprising tramadol and ibuprofen | |
| CA2350635A1 (en) | Therapeutic product and its use | |
| US6297286B1 (en) | Therapeutic use and formulation | |
| EP2002828B1 (en) | Solid pharmaceutical preparation | |
| Mystakidou et al. | Oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients: an overview of its pharmacological and clinical characteristics | |
| DE69918322T2 (en) | USE OF OPTICALLY PURE (R) -TOFIZOPAM FOR THE TREATMENT AND PREVENTION OF APPEARANCE | |
| CA2371822A1 (en) | Methods for treating apnea and apnea disorders using optically pure r(+)ondansetron | |
| EP1795207A1 (en) | Solid pharmaceutical preparation | |
| EP1697005B1 (en) | Combination of flupirtine and tramadol | |
| CA2423558A1 (en) | Delivery system for multi-pharmaceutical active materials at various release rates | |
| Likar et al. | Challenging the equipotency calculation for transdermal buprenorphine: four case studies | |
| AU2349899A (en) | Methods and compositions for aiding in smoking cessation and for treating pain and other disorders using optically pure (-)-bupropion | |
| MXPA01005242A (en) | Therapeutic product and its use | |
| WO1994021244A1 (en) | Method of treating addictive behaviors | |
| CA2338326A1 (en) | Use of moclobemide and metabolites for treating and preventing substance abuse | |
| US20020032197A1 (en) | Methods and compositions for using moclobemide | |
| RU2506947C2 (en) | Prolonged release tablet containing theobromin | |
| US20160317662A1 (en) | Stable oral pharmaceutical composition | |
| AU2003220743B2 (en) | Use of optically pure (+)-norcisapride for treating apnea, bulimia and other disorders | |
| KR20070004127A (en) | Methods of diminishing co-abuse potential |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |